Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Performance of Travoprost Intraocular Implant (iDose TR) in Glaucoma and Ocular Hypertension
NCT06582732Phase 2Completed
- Sponsor
- Glaukos Corporation
- Start
- Mar 2021
- Primary completion
- Nov 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of travoprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by Glaukos Corporation. Started Mar 2021; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT06582732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06582732.